• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Cannabidiol for Schizophrenia

Cannabidiol for Schizophrenia

January 1, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: McGuire P et al, Am J Psychiatry 2017;175(315). doi:10.1176/appi.ajp.2017.17030325

Type of study: Double-blind, randomized controlled trial

Traditional antipsychotic medications leave much to be desired. Their therapeutic response rate for schizophrenia is low, and their side effects are troubling and lead to high rates of noncompliance. Clearly, there is an urgent need for alternative agents. Although patients—including those diagnosed with schizophrenia—have long attested to the benefits of marijuana, only recently have researchers begun taking it seriously as a therapeutic option. In this pilot study, investigators evaluated the benefits of cannabidiol (CBD), which is one of the two main active components of marijuana (the other being THC), for the treatment of ­schizophrenia.

In this 6-week, double-blind, randomized controlled trial, adult patients diagnosed with schizophrenia or a related psychotic disorder were recruited from multiple sites across Europe. All patients were actively psychotic, though they could not be entirely ­treatment-resistant (ie, patients had to have displayed at least a partial response to antipsychotic medications). Patients entered the study only after they had been on a stable dosage of antipsychotic medication for at least 4 weeks, and this medication was continued throughout the course of the study. CBD was dosed at 1,000 mg/day in the form of an oral solution. Active substance use was not grounds for exclusion. The primary efficacy measure used was the Positive and Negative Syndrome Scale (PANSS), while cognition was measured using the Brief Assessment of Cognition in Schizophrenia (BACS) scale.

43 patients were randomized to CBD and 45 to placebo. Positive symptoms (eg, delusions or hallucinations) were significantly reduced at endpoint for patients receiving CBD compared to placebo. Improvement in negative symptoms (eg, flat affect) favored CBD, but this difference did not reach statistical significance. Patients receiving CBD also fared better on global assessment of functioning, clinicians’ global assessment of improvement, and cognitive measures, though this latter difference fell just short of statistical significance (p = 0.07). No major adverse events occurred that were attributed to CBD, and the participants were not able to tell if they were taking CBD or placebo.

TCPR’s Take
CBD’s therapeutic potential has received a lot of attention lately and is covered elsewhere in this issue. This is the most rigorous study of CBD in schizophrenia to date, and its intriguing findings warrant replication with a larger sample and longer duration. Given the many limitations and pitfalls associated with traditional antipsychotic medications, a novel compound that might be devoid of those pitfalls is a most welcome ­development.
General Psychiatry
KEYWORDS cannabidiol research-update schizophrenia
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Deprescribing, TCPR, January 2019
    Brexanolone: A New Treatment for Postpartum Depression
    Is Ketamine Just Another Opiate?
    Cannabidiol for Schizophrenia
    Wellbutrin Augmentation: When Does It Work?
    Deprescribing Medication
    Prescription CBD Is Available, But Are We Ready to Use It?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.